{
  "nctId": "NCT03788057",
  "briefTitle": "Inflammatory Indices in Predicting the Failure of Inhaled Corticosteroids Reduction in Young Participants With Asthma",
  "officialTitle": "Evaluation of the Usefulness of Induced Sputum Eosinophilia, eNO and Bronchial Hyperresponsiveness in Predicting the Failure of Inhaled Corticosteroids Dose Reduction in Children and Adolescents With Stable Asthma",
  "protocolDocument": {
    "nctId": "NCT03788057",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2018-12-25",
    "uploadDate": "2024-04-21T17:57",
    "size": 134102,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT03788057/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "NA"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NA",
  "interventionModel": "SINGLE_GROUP",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 58,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2016-02-01",
    "completionDate": "2019-03-31",
    "primaryCompletionDate": "2019-03-31",
    "firstSubmitDate": "2018-12-12",
    "firstPostDate": "2018-12-27"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* mild or moderate asthma with a stable course of at least 3 months:\n\n  * symptoms less than 4x per week,\n  * use of SABA below 3x a week,\n  * night awakening below 1x per week,\n  * FEV1\\> 80% of predicted\n  * no dose change in ICS or use of systemic steroids from 3 months\n* good adherence to treatment\n\nExclusion Criteria:\n\n* infection or exacerbation of asthma requiring the use of systemic steroids (or changes in the dose of inhaled steroids) in the last 3 months before the study\n* other chronic lung diseases or general diseases affecting the respiratory system\n* tobacco smoking\n* FEV1 below 80% of the predicted value",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "12 Years",
    "maximumAge": "18 Years",
    "stdAges": [
      "CHILD",
      "ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "The Percentage of Patients With Loss of Asthma Control",
        "description": "Criteria for loss of control (any of the following):\n\n* use of bronchodilators \\> 5 times a week\n* the need for treatment with oral corticosteroids\n* PEFR decrease \\>20% for 2 consecutive days, compared to the average run-in period",
        "timeFrame": "at 9 months"
      }
    ],
    "secondary": [
      {
        "measure": "Change in Sputum Eosinophilia",
        "description": "eosinophil percentage in induced sputum compared to baseline",
        "timeFrame": "at 1, 3, 4, 6 and 7 month"
      }
    ],
    "other": [
      {
        "measure": "Change in Airway Hyperresponsiveness to Hypertonic Saline",
        "description": "Airway hyperresponsiveness to hypertonic saline measured using combined method (together with sputum induction) and compared to baseline",
        "timeFrame": "at 1, 3, 4, 6 and 7 month"
      },
      {
        "measure": "Change in Airway Hyperresponsiveness (Exercise)",
        "description": "Airway hyperresponsiveness measured using an exercise challenge test and compared to baseline",
        "timeFrame": "at 2, 5 and 8 month"
      },
      {
        "measure": "Change in Exhaled NO",
        "description": "Measured every month and compared to baseline",
        "timeFrame": "months 1 - 8"
      },
      {
        "measure": "Change in Exhaled Breath Temperature (EBT)",
        "description": "Measured every month and compared to baseline",
        "timeFrame": "months 1 - 8"
      },
      {
        "measure": "Change in FEV1",
        "description": "Measured every month and compared to baseline",
        "timeFrame": "months 1 - 8"
      },
      {
        "measure": "Change in FVC",
        "description": "Measured every month and compared to baseline",
        "timeFrame": "months 1 - 8"
      },
      {
        "measure": "Change in FEF25-75",
        "description": "Measured every month and compared to baseline",
        "timeFrame": "months 1 - 8"
      }
    ]
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 1,
      "otherCount": 7,
      "totalCount": 9
    },
    "studyDesign": {
      "phases": [
        "NA"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "SINGLE_GROUP"
    },
    "overallComplexityScore": 33,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:29:21.886Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}